The Food and Drug Administration is ordering an unproven drug intended to prevent premature births off the market
FILE - This image provided by Covis Pharma shows packaging for the company's Makena medication. The Food and Drug Administration on Thursday, April 6, 2023 ordered the immediate market withdrawal of a drug intended to prevent premature births, which has remained available for years despite data showing it doesn't help pregnant women. The decision follows repeated efforts by Swiss drugmaker Covis Pharma to keep Makena on the U.S. market while it conducted additional studies.
The decision by FDA Commissioner Robert Califf and the agency's chief scientist marks the first time the FDA has formally forced the removal of a drug that it initially approved based on promising early data. In all prior cases, drugmakers voluntarily pulled medications after the FDA made clear it intended to order removal.
The FDA expedited Makena's approval in 2011 based on a small study suggesting it reduced rates of premature birth in women who had previously had trouble bringing a pregnancy to term. But results from a 1,700-participant study completed in late 2018 showed the drug neither reduced premature births — as originally thought — nor resulted in healthier outcomes for babies.
The FDA has faced pressure to crack down on unproven drugs cleared under its accelerated approval program, which since the early 1990s has allowed dozens of drugs to launch based on early results.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Where exactly each dollar you spend on food goes: farmers get 14 cents and 4 cents pays for packagingA new report examines what each food dollar pays for, from food processing to packaging.
Consulte Mais informação »
FDA plans to allow a second updated COVID booster for vulnerable AmericansThe FDA plans to allow older and immunocompromised Americans to get a second updated coronavirus booster shot in the near future, an acknowledgment of the virus’s continuing risks to vulnerable people.
Consulte Mais informação »
Eyedrops maker couldn't ensure factory was sterile, FDA saysThe Food and Drug Administration says it found a host of problems at an Indian manufacturing plant recently linked to contaminated eyedrops
Consulte Mais informação »
FDA to OK Second COVID Booster for People 65 and OlderPeople ages 65 and older and those with a weak immune system may choose to get a second COVID-19 bivalent booster shot starting later this spring, according to a new report.
Consulte Mais informação »
Eyedrops maker couldn't ensure factory was sterile, FDA saysThe Food and Drug Administration says it found a host of problems at an Indian manufacturing plant recently linked to contaminated eyedrops. FDA inspectors found about a dozen problems with how Global Pharma Healthcare made and tested the drops. The FDA released its preliminary inspection report Monday. Recalled eyedrops made at the plant have been linked to 68 bacterial infections in the U.S., including three deaths and eight cases of vision loss. Four people have had to have their eyeballs surgically removed due to infection. The outbreak is considered particularly worrisome because the bacteria driving it is resistant to standard antibiotics.
Consulte Mais informação »